Biological molecules are increasingly becoming a part of the therapeutics portfolio that has
been either recently approved for marketing or those that are in the pipeline of several …

Immune responses to protein and peptide drugs can alter or reduce their efficacy and may
be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical …

Severe asthma imposes a significant burden on patients, families and healthcare systems.
Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care …

Biologic agents have become a core component of therapeutic strategies for many
inflammatory rheumatic diseases. However, perhaps reflecting the specificity and generally …

Biologicals are crucial targeted therapeutic agents in oncological, immunological, and
inflammatory diseases, and their use in clinical practice is broadening. In recent years, the …

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …

In oncology, an increasing number of targeted anticancer agents and immunotherapies are
of biological origin. These biological drugs may trigger immune responses that lead to the …

Biopharmaceuticals have the potential to raise an immunogenic response in treated
individuals, which may impact the efficacy and safety profile of these drugs. As a result, it is …

Background Biopharmaceutical products (BPs) are widely used to treat autoimmune
diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our …

ABSTRACT A major impediment to successful use of therapeutic protein drugs is their ability
to induce anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a …